Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: Comparison with clinical, surgical and histological staging

BJU International

Volumn 95, Issue 9, 2005, Pages 1232-1236

  Nargund, Vinod ^a,b   Al Hashmi, Dona ^a   Kumar, Priya ^a   Gordon, Stephen ^a   Otitie, Ugo ^a   Ellison, David ^a   Carroll, Melvyn ^a   Baithun, Sohail ^a   Brihon, Keith E ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Histology; Localized prostate cancer; Radiolabelled PSMA; Staging

Indexed keywords

MONOCLONAL ANTIBODY MUJ591; MONOCLONAL ANTIBODY TC 99M; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER NECK; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; ISOTOPE LABELING; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RELIABILITY; SCINTIGRAPHY; SEMINAL VESICLE;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TECHNETIUM; YTTRIUM RADIOISOTOPES;

EID: 20444430506     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05511.x     Document Type: Article

References (26)

1. Montironi R. Prognostic factors in prostate cancer. BMJ 2001; 322: 378-9
2. Ravery V, Limot O, Tobolski F et al. Advances in the assessment of clinically localized prostate cancer. Eur Urol 1996; 29: 257-65
3. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long term results. J Urol 1990; 144: 1180-4
4. Gao X, Mohideen N, Flanigan RC, Waters WB, Wojcik EM, Leman CR. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. J Urol 2000; 164: 1982-6
5. Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995; 195: 86-90
6. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urol 1993; 41: 207-16
7. Partin A, Yoo J, Carter H et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
8. Rifkin M, Zerhouni E, Gatsonis C et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 1990; 323: 621-6
9. Levran Z, Gonzales JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778-81
10. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153: 1543-8
11. Sakr WA, Wheeler TM, Blute M et al. Staging and reporting of prostate cancer - sampling of the radical prostatectomy specimen. Cancer 1996; 78: 366-8
12. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
13. Murphy GP. Lucy Wortham James Basic Research Award. Markers of prostatic carcinoma. Arch Surg 1991; 126: 1404-7
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasis. Urology 1998; 52: 637-40
15. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropetidase. Proc Natl Acad Sci USA 1996; 93: 749-53
16. Wynant GE, Murphy GP, Horoszewicz JS et al. Immunoscintigraphy of prostate cancer: preliminary results with 111In-labelled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991; 18: 229-41
17. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumour vascular epithelium. Cancer Res 1997; 57: 3629-34
18. Liu H, Rajasekaran AK, Moy P et al. Constitutive and antibody-induced internalisation of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055-60
19. Bander NH, Trabulsi EJ, Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabelled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-21
20. Smith-Jones PM, Vallabahajosula S, Navarro V, Goldsmith SJ, Bander NH. Y-90 huJ591 Mab specific to PMSA radioimmunotherapy, RIT. Studies in nude mice with prostate cancer LNCaP tumour. Eur J Nucl Med 2000; 27: 951
21. Feneley MR, Chengazi VU, Kirby RS et al. Prostatic radioimmunoscintigraphy: preliminary results using a technetium-labelled monoclonal antibody, CYT-351. Br J Urol 1996; 77: 373-81
22. Chengazi VU, Feneley MR, Ellison D et al. Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). J Nucl Med 1997; 38: 675-82
23. Stalteri MA, Mather SJ. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation. Eur J Nucl Med 1996; 23: 42-4
24. Ellison D, Stalteri MA, Mather SJ. Photoreduction of monoclonal antibodies for conjugation and fragmentation. Biotechniques 2000; 28: 318-26
25. Mather SJ, Ellison D. Reduction-mediated technetium-99m labelling of monoclonal antibodies. J Nuc Med 1990; 31: 692-7
26. Britton KE, Feneley MR, Jan H, Chengazi VU, Granowska M. Prostate cancer: the contribution of nuclear medicine. BJU Int 2000; 86 (Suppl. 1): 135-42